当心噻嗪类药物造成的低钠血症

2018-01-23 李京艳 医学界内分泌频道

老人家因心律失常和高血压入院,却在住院期间意外出现低钠血症,谁是元凶?

九月的一天,医院同事找我,说自己的奶奶一般状况不错,只是最近血压控制不好,想来住院调整。同事之间帮个忙是应该的,找我也是对我的信任,于是爽快答应。

入院后,对症治疗

老人家来了,果然一般状况很好。

主诉:间断心悸伴双下肢麻木3月,既往高血压病史30年,最高血压200/80mmHg,规律服用“非洛地平缓释片”降压治疗。否认糖尿病史,否认药物过敏史。

查体及实验室检查:入院血压170/70mmHg,其他阳性体征包括左侧足背动脉搏动减弱。心电图提示,窦性心律,ST-T改变。当日急查心肌酶,电解质,肾功能均正常,其中,血钾3.7 mmol/L, Na137 mmol/L,Cl 100 mmol/L。

初步诊断:冠状动脉性心脏病,心律失常?心功能II级(NYHA),高血压病3级(极高危),下肢动脉硬化闭塞症?给予单硝酸异山梨酯改善循环,厄贝沙坦氢氯噻嗪降压治疗。

入院后完善检查:血常规,凝血功能,肝肾功能正常。

超声心动图提示:主动脉瓣钙化,二、三尖瓣轻度反流,左室舒张功能减低,左室收缩功能正常。

颈部及下肢血管彩超提示:各动脉内中膜增厚伴多发附壁斑块形成,伴不同程度狭窄,最严重者左侧胫前动脉狭窄大于70%,左侧足背动脉供血不足。

进一步予以西洛他唑抗血小板聚集,前列地尔扩张血管,瑞舒伐他汀稳定斑块,雷贝拉唑抑酸护胃治疗。

患者间断心悸,心电图可见室性早搏,予以稳心颗粒及门冬氨酸钾镁治疗。患者睡眠欠佳,予以唑吡坦改善睡眠治疗。

至此,满以为找到了老人家的症结所在,治疗也规范无误,只等病情逐日好转了。

突发低钠血症,符合SIADH,但……

住院第6天,患者出现恶心,呕吐,为胃内容物,伴心悸,心电监护提示室性早搏二联律,急查电解质回报,血K+ 2.9 mmol/L, Na+120mmol/L,Cl- 83 mmol/L,嘱予以高钠饮食,补充氯化钾,抑酸对症治疗。

次日,复查血K+正常,4.5mmol/L, Na+ ,Cl-上升,分别为125 mmol/L, 89mmol/L,继续补充食盐胶囊治疗。联系心脏科,加用美西律150mg,每日3次,抗心律失常治疗。

针对患者住院期间出现的低钠血症,首先考虑由消化道症状引起,结合已查的甲状腺功能、肾上腺皮质功能,除外了甲状腺功能低下、肾上腺皮质功能低下。进一步完善尿电解质,提示尿钠浓度降低,血、尿渗透压分别为241、306 mosm/kgH2O,符合抗利尿激素分泌失调综合征(SIADH),于是病因分析,需除外肿瘤,感染,中枢神经系统疾患等。头MRI,胸CT,腹部超声均未见明显有意义的异常,建议必要时行PET-CT检查除外恶性肿瘤。

医生的分析言之凿凿,同事作为家属,虽情感上难以接受,但行动上给予了我们最大程度的信任、理解和配合。

住院第9天,复查血K+ 4.1mmol/L, 血Na+却降至109mmol/L,血Cl- 76mmol/L。经心脏科医生会诊,科内的病例讨论,为避免现有药物的干扰,停用了厄贝沙坦氢氯噻嗪,美西律,唑吡坦,并限水,予以呋塞米5毫克静脉推注,8小时后血钠上升至120mmol/L,患者消化道症状好转,继续限水,血钠以每日增长5 mmol/L的速度上升,至住院第13天,患者血钠上升至134 mmol/L。遂病情好转出院。院外随访3月,患者一般情况良好,复查血钠正常。

回顾病例,究竟元凶是谁?

老人家因心律失常和高血压入院,却在住院期间意外出现低钠血症,经更换药物、限水和呋塞米治疗好转,究竟元凶是什么呢?

在患者出现低钠血症之初,我们的诊断思路是:患者血钠↓,尿钠↑,血渗透压↓,尿渗透压>100osm/kgH20,无低血容量临床表现(血尿素氮,肌酐,尿酸下降),除外了甲减,肾皮低,虽患者入院后应用了厄贝沙坦氢氯噻嗪降压,但根据既往的临床经验,认为每日12.5毫克氢氯噻嗪不足以引起和解释患者的低钠血症,所以临床考虑SIADH,这也是老年人低钠血症的最常见的原因。

SIADH常见于恶性肿瘤,肺部疾病,中枢神经系统疾病,炎症、药物(包括抗癫痫药、抗抑郁药、秋水仙碱等)、外科手术等。

循此思路,查找病因,却忽略了一部分噻嗪类利尿剂诱发的低钠血症患者,总水量是增多的,血容量可以接近正常,类似于SIADH。患者合并低钾血症,也有利于噻嗪类诱发低钠血症的诊断。同时,可能由于消化道症状的存在,刺激了抗利尿激素的分泌,导致轻度SIADH。

因此,患者经停药、限水、呋塞米(排水多于排钠)的治疗后,血钠逐步上升。曾有文献报道,度洛西丁与厄贝沙坦氢氯噻嗪联用,导致患者出现严重低钠血症,其机制即度洛西丁引起的SIADH和氢氯噻嗪引起的失钠。

噻嗪类利尿剂导致的低钠血症,机制复杂,至今仍未完全阐明。它通过阻断远端肾小管噻嗪类敏感的钠氯协同转运蛋白,抑制钠离子和氯离子的重吸收,降低肾脏排水能力,还可以促进钠由细胞外转移至细胞内。

那么,对老年患者,应用血管紧张素受体阻滞剂和噻嗪类利尿剂的复方制剂降压是否恰当呢?

2016年,ESH/EUGMS发表的高龄衰弱老年高血压管理的专家建议指出,收缩压高于160mmHg,作为启动降压治疗的界值,控制目标是小于150 mmHg,但不低于130 mmHg,钙通道阻滞剂、噻嗪类利尿剂与血管紧张素转换酶抑制剂应作为高龄患者的优选降压药物。

老年高血压的诊断与治疗中国专家共识(2017版)亦强调,临床常用的钙通道阻滞剂、利尿剂、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂及β受体阻滞剂,均可用于老年高血压的初始治疗。

但值得注意的是,临床策略为小剂量开始,平稳降压;慎重选药,严密观察;多药联合,逐步达标;因人而异,个体化治疗。所以,具体到每一位患者,须严密观察其正副作用。

病例反思

1、医生对患者的血钠变化应该更加敏感。严重的低钠血症,可导致脑水肿和昏迷,但低钠血症如果纠正过快,又会导致中枢神经系统脱髓鞘病变。

2、住院期间出现的病情变化,不仅要考虑到患者已知疾病的变化,或者合并其他潜在的疾病,还应考虑到药物少见的副作用。

最后想说,老人家受苦了,感谢患者和家属给予的配合和支持。永远记得,病人教会我们成长。

附表 低钠血症诊断流程


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-09-01 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 131****1460

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 惠映实验室

    学习了.谢谢分享.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1643229, encodeId=e1b01643229f8, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Sep 01 16:46:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361380, encodeId=bc6d13613802a, content=<a href='/topic/show?id=835426385a6' target=_blank style='color:#2F92EE;'>#低钠血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26385, encryptionId=835426385a6, topicName=低钠血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538267, encodeId=3e33153826e1f, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Jan 25 08:46:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281316, encodeId=ec4c28131631, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Jan 23 19:45:12 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281285, encodeId=afd7281285cc, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jan 23 19:04:03 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281280, encodeId=52fc281280cc, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Tue Jan 23 18:18:08 CST 2018, time=2018-01-23, status=1, ipAttribution=)]
    2018-01-23 orangesking

    0

相关资讯

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖

利尿剂这么多,临床该怎么选?

1.碳酸酐酶抑制剂 代表药物— 乙酰唑胺 • 碳酸酐酶主要存在于肾皮质、红细胞、中枢神经系统、胃黏膜、眼睫状上皮细胞 • 利尿作用弱、易产生耐受性 • 长期应用可引起“代酸”,可治疗“代碱” • 可减少房水形成降眼压,缓解青光眼症状 • 可抑制脑组织及脉络

更换或添加药物或可解决噻嗪类诱导糖尿病

  英国学者的一项研究表明,替换药物或添加阿米洛利可能是预防噻嗪类诱导糖尿病的解决方案。论文于2012年4月9日在线发表于《高血压》(Hypertension)杂志。   高血压指南建议限制噻嗪类利尿剂用量并避免联用β受体阻滞剂,原因在于其可升高糖尿病风险。研究者实施了两项双盲、安慰剂对照、交叉研究。在纳入41例患者的第一项研究中,苄氟噻嗪治疗4周后可检查到2小时口服糖耐量试验时的血糖

利尿剂:安全、有效、毫无争议的一线降压药!

噻嗪类利尿剂具有肯定的降压效果、可靠的靶器官保护作用以及良好的安全性和耐受性,但是目前临床中应用很少。2009年China STATUS研究分析了92家三甲医院5086例高血压患者,发现我国高血压人群利尿剂使用率仅10%。利尿剂是各国高血压指南中毫无争议的一线降压药物。然而,由于很多临床医生对此来药物的安全性存在不正确的认识,导致其临床作用与优势未能充分发挥。

噻嗪类利尿剂存在显著效力差异

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血